<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367197">
  <stage>Registered</stage>
  <submitdate>2/10/2014</submitdate>
  <approvaldate>10/10/2014</approvaldate>
  <actrnumber>ACTRN12614001086651</actrnumber>
  <trial_identification>
    <studytitle>Effects of Fenofibrate on Intramyocardial Triglyceride Content and Left Ventricular Myocardial Function in patients with Type 2 Diabetes and Hypertriglyceridemia</studytitle>
    <scientifictitle>Effects of Fenofibrate on Intramyocardial Triglyceride Content and Left Ventricular Myocardial Function in patients with Type 2 Diabetes and Hypertriglyceridemia</scientifictitle>
    <utrn>U1111-1162-5325</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes</healthcondition>
    <healthcondition>Hypertriglyceridemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Daily oral administration of 145mg of fenofibrate for 6 months. Drug tablet return will monitor adherence.</interventions>
    <comparator>Placebo tablets. The frequency and duration of use will also be identical to the active drug.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Intramyocardial triglyceride content by MRI. </outcome>
      <timepoint>6 months post commencement of drug/placebo.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Myocardial deformation by speckle tracking echocardiography.</outcome>
      <timepoint>6 months post commencement of drug/placebo.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Intrahepatic triglyceride level by MRI.</outcome>
      <timepoint>6 months post commencement of drug/placebo.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Type 2 diabetes
2. Hypertriglyceridemia</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Atrial fibrillation
2. Current use of any fenofibrate or related fibrates 
3. Contraindication to fenofibrate including: liver impairment demonstrated by abnormal liver function tests (greater than or equal to 3 times normal upper limit), chronic renal failure (eGFR &lt;60mL/min), symptomatic gallbladder disease, myopathy/myositis (elevation of CK &gt; 5 times upper limit of normal)
4. Contraindication to MRI including use of Gadolinium contrast
5. Current enrolment in any other drug trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Trial participants who meet the inclusion/exclusion criteria and provide Informed Consent. Allocation concealment is performed by sealed opaque envelopes. Fenofibrate/Placebo tablets will be provided in numbered containers. Central randomization is performed via a central computer. </concealment>
    <sequence>The patients will be allocated to treatment groups by use of block randomization with strata defined by gender, each with separate computer-generated treatment allocation sequences with permuted block sizes in random order. All trial staff, investigators and participants are blinded to the randomization schedule.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/06/2014</anticipatedstartdate>
    <actualstartdate>15/06/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <postcode>4102 - Woolloongabba</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Arnold Ng</primarysponsorname>
    <primarysponsoraddress>Princess Alexandra Hospital, The University of Queensland
199 Ipswich Road, Woolloongabba, QLD 4102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Abbott</sponsorname>
      <sponsoraddress>32-34 Lord St
Botany, NSW 2019
Locked Bag 5016
Botany, NSW 1455</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a single-centre, randomized, double-blind, placebo-controlled clinical trial. Participants will be randomized to receive fenofibrate (145mg daily for 6 months) or placebo in a parallel group, double blind design. Participants will undergo a cardiac MRI, Adenosine stress MRI perfusion, echocardiography and ECG at baseline and 6 months. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Metro South Human Research Ethics Committee</ethicname>
      <ethicaddress>Princess Alexandra Hospital
199 Ipswich Road, Woolloongabba, QLD 4102</ethicaddress>
      <ethicapprovaldate>20/11/2012</ethicapprovaldate>
      <hrec>HREC/12/QPAH/478</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Arnold Ng</name>
      <address>Princess Alexandra Hospital, The University of Queensland
199 Ipswich Road, Woolloongabba, QLD 4102</address>
      <phone>61731762111</phone>
      <fax />
      <email>uqcng6@uq.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Arnold Ng</name>
      <address>Princess Alexandra Hospital, The University of Queensland
199 Ipswich Road, Woolloongabba, QLD 4102</address>
      <phone>61731762111</phone>
      <fax />
      <email>uqcng6@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Arnold Ng</name>
      <address>Princess Alexandra Hospital, The University of Queensland
199 Ipswich Road, Woolloongabba, QLD 4102</address>
      <phone>61731762111</phone>
      <fax />
      <email>uqcng6@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Arnold CT Ng</name>
      <address>Princess Alexandra Hospital, The University of Queensland
199 Ipswich Road, Woolloongabba, QLD 4102</address>
      <phone>61731762111</phone>
      <fax />
      <email>uqcng6@uq.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>